Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Losartan Experimental Workflows for AT1 Biology
2026-09-09
Losartan is a practical angiotensin II receptor antagonist for connecting AT1 signaling with vascular smooth muscle behavior, blood-pressure biology, and stromal remodeling. This workflow-focused guide shows how to control compound handling, separate receptor-specific effects from toxicity, and extend vascular assays toward the collagen-rich tumor microenvironment described in recent research.
CDK4/6–BET Synergy in Pancreatic Cancer
2026-09-08
Gu et al. show that palbociclib can suppress pancreatic ductal adenocarcinoma cell growth while paradoxically increasing migration, invasion, and epithelial-to-mesenchymal transition. Combining CDK4/6 inhibition with the BET inhibitor JQ1 enhanced antitumor activity and countered this invasive phenotype through coordinated regulation of GSK3β-mediated Wnt/β-catenin and TGF-β/Smad signaling.
EZ Cap™ Human PTEN mRNA (ψUTP): Assay Guide
2026-09-08
A scenario-based laboratory guide to using EZ Cap™ Human PTEN mRNA (ψUTP), SKU R1026, in mammalian viability, proliferation, and cytotoxicity workflows. It connects Cap1, pseudouridine, and poly(A) design with practical controls, handling, pathway interpretation, and vendor-selection criteria.
High-Content Screening of Schistosome Stem Cells
2026-09-07
Perera, Chioni, and Walker developed a quantitative high-content platform that measures somatic neoblast proliferation in developmentally advanced liver-stage Schistosoma mansoni schistosomula. Screening a stem cell-focused compound collection identified prioritized molecules that disrupted parasite development and stem cell proliferation, demonstrating how cellular phenotyping can strengthen anti-schistosomal lead discovery.
From Nanoparticle Killing to Viability Evidence
2026-09-07
A translational framework for using Calcein AM/PI fluorescence to connect nanoparticle disinfection efficacy with mammalian cell compatibility in root canal research.
FUS–SMN Phase Separation in Neuronal Granules
2026-09-05
Wang and Li show that asymmetric dimethylation of FUS creates binding sites for the oligomeric Tudor-domain protein SMN, enabling multivalent interactions that promote liquid–liquid phase separation and neuronal granule assembly. The study links impaired methylation or reduced SMN valency to defective axonal mRNA distribution and neuronal phenotypes, providing a mechanistic framework for understanding granule dysfunction in spinal muscular atrophy.
Itraconazole for Candida Biofilm Assays
2026-09-04
Itraconazole combines triazole antifungal activity with practical value in Candida biofilm, resistance, CYP3A4, hedgehog, and angiogenesis studies. This workflow shows how to control solubility, separate planktonic from biofilm effects, and test PP2A–autophagy-dependent drug resistance without overinterpreting cross-species potency.
Live-Dead Cell Staining Kit in 3D Culture
2026-09-04
Explore how the Live-Dead Cell Staining Kit can turn viability imaging into a matrix-aware decision tool for 3D culture. This guide connects Calcein-AM Propidium Iodide staining with hydrogel formulation, flow cytometry, microscopy, and more defensible interpretation of cell injury.
JAK Inhibitors Block RA Synovial Fluid Pain Signaling
2026-09-03
This preprint identifies a direct effect of JAK inhibition on human sensory neurons exposed to rheumatoid arthritis synovial fluid. By combining cytokine profiling, transcriptomics, phospho-STAT3 analysis, and neuronal electrophysiology, it links synovial JAK/STAT signaling to pain-relevant neuronal responses and provides a mechanistic rationale for further study of JAK inhibitor analgesia.
Hybridization Rewired Pluripotency in Xenopus laevis
2026-09-03
Phelps and colleagues show that hybridization remodeled early embryonic gene regulation in allotetraploid Xenopus laevis, causing divergent activation of L- and S-subgenome homeologs while preserving the total dosage of core pluripotency genes. By combining homeolog-resolved RNA sequencing, transcriptional perturbation, chromatin accessibility profiling, and CUT&RUN, the study links altered enhancer architecture to a dosage-buffered developmental network.
Abiraterone acetate in 3D Prostate Models
2026-09-02
Build a translational workflow around Abiraterone acetate, from solvent-controlled dose response to patient-derived prostate spheroids. The approach separates CYP17 pathway engagement from simple viability loss, helping researchers interpret why three-dimensional cultures may respond differently from conventional cell lines.
GDC-0994: ERK1/2 Inhibition Workflow
2026-09-02
GDC-0994 is a potent, selective ERK1/2 inhibitor for testing MAP kinase dependence in mutant RAS/BRAF cancer models and ERK-linked cholestasis assays. This practical guide covers compound preparation, phosphoprotein validation, zebrafish endpoints, dose optimization, and troubleshooting across both applications.
CDK4/6–BET Synergy in Pancreatic Cancer
2026-09-01
Gu et al. show that combining the CDK4/6 inhibitor palbociclib with the BET inhibitor JQ1 can counter a major limitation of CDK4/6 blockade in pancreatic ductal adenocarcinoma: increased migration, invasion, and epithelial-to-mesenchymal transition. The study links this synergy to coordinated regulation of GSK3β-mediated Wnt/β-catenin signaling and TGF-β/Smad crosstalk, providing a mechanistic rationale for combination treatment.
Losartan and AT1 Signaling: From Vessels to Tumors
2026-09-01
Losartan is an angiotensin II receptor antagonist used to dissect AT1 signaling in vascular and stromal biology. This article connects hypertension research with tumor-microenvironment assay design while clarifying what recent ARB evidence does—and does not—demonstrate.
Glabridin–Gold(I) Complex Reprograms Tumor Immunity
2026-08-31
The reference study introduces complex 6d, which combines an N-heterocyclic carbene gold(I) center with glabridin to coordinate TrxR and MAPK pathway modulation. In liver cancer models, this design strengthens dendritic-cell activity while reducing several immunosuppressive cell populations, providing a mechanistic basis for combination strategies with cancer immunotherapy.
8296 records 9/554 page Previous Next First page 上5页 678910 下5页 Last page